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Background/aim: The aim of this study is to evaluate the epidemiological and clinical characteristics and parameters that determined the
clinical course and prognosis of the COVID-19 patients admitted to Ankara City Hospital during the first month of the pandemic in Turkey.
Materials and methods: SARS-CoV-2 PCR positive patients who were hospitalized between March 10 and April 10, 2020 were included.
Results: Among 222 patients, mean age was higher in severe acute respiratory illness (SARI)/critical disease group (P < 0.001). Median time
from illness onset to admission and presence of comorbidity, especially coronary artery disease and chronic obstructive pulmonary disease,
were significantly higher in the SARI/critical disease group (P < 0.05). Cough and fever were the most common symptoms, while anosmia
and loss of taste were observed in 8.6% and 7.7% patients, respectively. The mortality rate was 5.4%. A high neutrophil/lymphocyte ratio;
low lymphocyte, monocyte, and platelet count; elevated liver enzymes; low GFR; and high levels of muscle enzymes, ferritin, and IL-6 on
admission were found to be associated with SARI/critical disease (P < 0.05). Bilateral ground-glass opacity and patchy infiltration were more
frequently seen in the SARI/critical disease group (P < 0.001). Patients older than 65 years had an 8-fold increased risk for development of
SARI/critical disease.
Conclusion: This cohort study regarding COVID-19 cases in Turkey reveals that older age, presence of comorbidity, bilateral infiltration on
CT, high neutrophil/lymphocyte ratio, low monocyte and platelet count, elevated liver enzymes, low GFR, high levels of muscle enzymes,
and high levels of ferritin and IL-6 on admission are predictors of SARI and severe disease.
Key words: COVID-19, Turkey, epidemiology, prognosis, IL-6, mortality

1. Introduction
On December 31, 2019, the World Health Organization
(WHO) China Country Office reported pneumonia cases
of unknown etiology in Wuhan, Hubei Province, China.
On January 7, 2020, the causative agent was identified as a
new Coronavirus (2019-nCoV), which had not previously
been detected in humans [1]. Later, the name of 2019nCoV disease was accepted as COVID-19, and the virus
was named SARS-CoV-2 because of its close resemblance
to SARS CoV. After this date, the number of patients
increased rapidly, and the WHO declared an “International
Public Health Emergency” regarding the coronavirus
outbreak at its meeting on January 30, 2020.

Although the world was caught unprepared to the
sudden emergence and rapid spread of the COVID-19
outbreak, Turkey managed to postpone the emergence of
the disease within its borders through the implementation
of effective preventive measures until March 11, 2020,
when the first case was detected. After cases seen in China,
Italy, and Spain starting from January, Turkey executed a
meticulous monitoring and evaluation process to decide,
implement, and follow up with comprehensive and timely
measures. These measures have given time to be prepared
for both the community and the healthcare system in
this pandemic. Furthermore, since the beginning of the
pandemic, Turkish citizens infected with COVID-19 have
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been treated free of charge and all equipment, tests, kits,
drugs that are used during diagnosis and treatment are
provided by the Ministry of Health.
The aim of this study is to evaluate the epidemiological
and clinical characteristics of the COVID-19 patients
admitted to the Ankara City Hospital and to reveal the
factors and parameters that determine the clinical course
and prognosis of the patients. Ankara City Hospital, the
largest hospital in Europe with a total of 3811 beds (723
of which are intensive care unit beds), employs 16,000
healthcare workers and is the major pandemic response
center in Ankara.
2. Materials and methods
Patients older than 18 years who were hospitalized in
Ankara City Hospital between March 10 and April 10,
2020, and who were found PCR positive for SARS-CoV-2
in oropharyngeal/nasopharyngeal swab samples or deep
tracheal aspiration were included. Patients who had no
follow-up for at least 14 days were excluded from the study.
Demographic features such as age, sex, place of
residence, symptoms and onset time, travel history,
comorbidities, physical examination, fever, and vital
signs for clinical responses were recorded from the
follow-up charts. Laboratory tests such as complete blood
count, blood chemical analysis (including renal and liver
function), coagulation parameters, acute phase reactants
(ferritin, C-reactive protein (CRP), procalcitonin (PCT),
and interleukin-6 (IL6)), and cardiac markers (creatin
kinase (CK), CK-MB, myoglobin, cardiac troponins,
and pro-BNP) in patients deemed necessary were also
obtained. Both X-ray and computed tomography (CT) of
the chest were used for radiological assessment. Control
radiography and CT were performed in patients with
clinical deterioration or in case of no response to the
medical treatment.
We classified COVID-19 patients into five groups
according to WHO guidelines (mild illness, pneumonia,
severe pneumonia, acute respiratory distress syndrome
(ARDS), and sepsis/septic shock). For comparisons,
patients were divided into two categories (mild disease/
pneumonia and severe acute respiratory illness (SARI)/
critical disease). The critical disease category consisted of
severe pneumonia, ARDS, sepsis, and septic shock.
The study was approved by the Turkish Ministry of
Health and the Ankara City Hospital Ethical Committee.
2.1. Statistical analysis
In the statistical analysis of the data, SPSS 18.0 was used.
Numbers and their percentages were used for categorical
variables in descriptive statistics. Mean, standard deviation,
median, and range (minimum–maximum) were used for
numerical variables. For categorical variables, the chisquare test was used. When the chi-square condition was
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not met, Fisher’s exact test was used. Continuous variables
were analyzed with Student’s t-test, and when parametric
test conditions were not met, the Mann–Whitney U
test was used. Logistics regression analysis was used for
multivariate analysis. A P-value < 0.05 was considered
statistically significant.
3. Results
A total of 222 (59.5% male, 40.5% female) patients
were included in the study. Demographic and clinical
characteristics of the patients are summarized in Table
1. Mean age was 50.6 ± 16.5 (18–93) years and mean age
in the SARI/critical disease group was higher (47.7 ±
16.1 vs 62.2 ± 11.9 years, P < 0.001). Fifty (22%) patients
had SARI or critical disease. Of the patients, 35% had a
known contact with a COVID-19 patient. Of the patients,
12.6% were healthcare workers (HCW) employed in
different hospitals in Ankara including Ankara City
Hospital. Out of 26 HCW patients, 3 were in the SARI/
critical disease group. All HCWs survived. Among all
patients, 60 (27%) patients had history of travel abroad.
Median time from illness onset to admission was 3 (0–21)
days and was higher in SARI/critical disease group. At
least one comorbidity was present in 92 (41.4%) patients.
Presence of comorbidity, especially coronary artery
disease and chronic obstructive pulmonary disease, was
significantly higher in SARI/critical disease group (P <
0.05). Comorbidities are given in Table 2. Characteristics
of the patients in terms of symptoms are given in Tables 1
and 3. Cough and fever were the most observed symptoms
on admission, 58.1% and 48.6%, respectively. Anosmia
and loss of taste were observed in 19 (8.6%) and 17 (7.7%)
patients, respectively. Latest improved symptoms were
fatigue, myalgia/arthralgia, loss of appetite, and dyspnea.
Among 222 patients, 197 (88.7%) had positive PCR
for SARS-CoV-2 on admission. The second samples taken
48 h after the first PCR test were positive in 25 (11.3%)
patients. Median day for the first negative test after positive
PCR was 5 (1–20). An influenza test was performed in
169 patients and only one (0.6%) patient had a positive
result. On admission, 62 patients received oseltamivir
treatment. Five (3.6%) patients had positive test results for
another respiratory virus. Secondary bacterial infection
was observed in 8 patients (3.6%). Overall mortality rate
among these patients was 5.4%. Median age of mortal
cases was 69 (44–81).
Complications are summarized in Table 4. Twentyone complications occurred in 20 patients. Complications
regarding thrombosis were observed in 4 patients. Immune
thrombocytopenic purpura (ITP) occurred in one patient.
Four patients who had complications were in the mild
disease/pneumonia group.
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Table 1. Clinical and demographic characteristics of COVID-19 patients.
All patients

Disease severity
Mild disease and
pneumoniae (n = 172)

SARI and critical
disease (n = 50)

P-value

50.6 ± 16.5 (18–93)

47.7 ± 16.1

62.2 ± 11.9

<0.001

<30 years

27 (12.2%)

26 (15.1%)

1 (2.0%)

<0.001

30-64 years

143 (64.4%)

120 (69.4%)

23 (46.0%)

65-74 years

41 (18.5%)

20 (11.6%)

21 (42.0%)

≥75 years

11 (5.0%)

6 (3.5%)

5 (10.0%)

>65 years

52 (23.4%)

26 (50.0%)

26 (50.0%)

≤65 years

170 (76.6%)

146 (85.9%)

24 (14.1%)

Age (mean)
Age group

Age group
<0.001

Sex
Male (n = 137)

132 (59.5%)

99 (57.6%)

33 (66.0%)

Female (n = 92)

90 (40.5%)

73 (42.4%)

17 (34.0%)

Days from illness onset to admission
(median. min–max)

3 (0–21)

3 (0–15)

3 (0–21)

<0.001

Any symptom (at least one)

202 (91.0%)

153 (89.0%)

49 (98%)

0.052

Fever

108 (48.6%)

76 (44.2%)

32 (64.0%)

0.013

Cough

129 (58.1%)

96 (55.8%)

33(66%)

0.199

Sputum

4 (1.8%)

1 (0.6%)

3 (6.0%)

0.11

Sore throat

36 (16.2%)

34 (19.8%)

2 (4.0)

0.008

Runny nose

11 (5.0%)

11 (6.4%)

-

0.130

Dyspnea

60 (27.0%)

32 (18.6%)

28 (56.0%)

<0.001

Myalgia

37 (16.7%)

31 (16%)

6 (12.0%)

0.314

Nausea/vomiting

21 (9.5%)

15 (8.7%)

6 (12.0%)

0.582

Diarrhea

18 (8.1%)

16 (9.3%)

2 (4.0%)

0.376

Fatigue

55 (24.8%)

43 (25.0%)

12 (24.0%)

0.885

Loss of appetite

7 (3.2%)

6 (3.5%)

1 (2.0%)

1

Headache

31 (14.0%)

28 (16.3%)

3 (6.0%)

0.65

0.285

Symptoms, no./total no (%) on admission

Laboratory findings of the patients are given in Table 5.
Low lymphocyte count, high neutrophil/lymphocyte ratio,
low monocyte count, low platelet count, elevated liver
enzymes, low GFR, high levels of muscle enzymes, and
high levels of ferritin and IL-6 on admission were found to
be associated with SARI/critical disease (P < 0.05).
Chest CT findings on admission of COVID-19 patients
are given in Table 6. CT was normal in 26 (12.1%) patients.
Consolidation was observed in 31 (14.4%) patients.
Bilateral ground-glass opacity (52.1% vs 91.7%) and patchy
infiltration (5.4% vs 22.9%) were more frequently seen in
the SARI/critical disease group (P < 0.001). Unilateral
ground-glass opacity was observed in 42 patients (25.1%)

in the mild disease group, whereas it was not observed in
any patient in the SARI/critical disease group.
In the mild disease group, 5 (2.3%) patients received
no treatment. Among all patients, 171 (77%) received
hydroxychloroquine alone or in combination with
azithromycin or doxycycline. Of the patients, 46 (23%)
received favipiravir alone or in combination with
hydroxychloroquine, azithromycin, or doxycycline.
Drug-induced QT prolongation was observed in 3 (1.4%)
patients who received hydroxychloroquine alone or in
combination with azithromycin or doxycycline.
Supportive treatment regimens of the patients are
given in Table 7. The most commonly used supportive
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Table 2. Comorbidities of COVID-19 patients.
All patients

Disease severity
Mild disease and
pneumonia (n = 172)

SARI and critical
disease (n = 50)

P-value

Any comorbidity

92 (41.4%)

63 (36.6%)

21 (42.0%)

0.007

Hypertension

52 (23.4%)

36 (20.9%)

16 (32.0%)

0.104

ACEI

19 (8.6%)

14 (8.1%)

5 (10.0%)

0.774

ARB

14 (6.3%)

8 (4.7%)

6 (12.0%)

0.091

ACEI or ARB

32 (14.4%)

22 (12.8%)

10 (20.0%)

0.201

Coronary artery disease

15 (6.8%)

8 (4.7%)

7 (14.0%)

0.048

Cardiovascular disease

56 (23.6)

36 (20.9%)

20 (40.0)

0.006

Diabetes mellitus

30 (13.5%)

20 (11.6%)

10 (20%)

0.127

COPD

12 (5.4%)

6 (3.5%)

6 (12.0%)

0.019

Obesity

77 (34.8%)

57 (33.0%)

20 (40.0%)

0.384

Chronic renal disease

6 (2.7%)

5 (2.9%)

1 (2.0%)

1

Malignancy

9 (4.1%)

6 (3.5%)

3 (6.0%)

0.425

ACEI: Angiotensin-converting-enzyme inhibitor, ARB: Angiotensin II receptor blocker, COPD: Chronic
obstructive pulmonary disease

Table 3. Median Duration of symptoms in COVID-19 patients.
Symptom

Days

Fever

3 (1–20)

Cough

4 (1–20)

Dyspnea

4.5 (1–18)

Sputum

4.5 (2–10)

Sore throat

2 (1–11)

Runny nose

3 (2–11)

Myalgia/arthralgia

5 (1–14)

Nausea/vomiting

3 (1–12)

Diarrhea

3 (1–7)

Fatigue

5 (2–20)

Loss of appetite

5 (2–10)

Headache

3.5 (1–12)

Anosmia

4 (1–10)

Loss of taste

4 (1–7)

Chills

3(1–8)

treatment agent was tocilizumab (12 patients, 5.4%). Four
patients receiving tocilizumab died. Oxygen therapy was
required in 56 (25.2%) patients. Of the patients, 42 (18.9%)
were followed up in the intensive care unit (ICU). Prone
position and noninvasive mechanical ventilation were
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Table 4. Complications of COVID-19 patients.
Any complication

21 (9.4%)

ARDS

12 (5.4%)

Pulmonary thromboembolic

3 (1.3%)

Septic shock

2 (0.9%)

Cerebral sinus venous thrombosis

1 (0.45%)

Rheumatic involvement

1 (0.45%)

Deep vein thrombosis

1 (0.45%)

Hepatitis (liver injury)

1 (0.45%)

ITP

1 (0.45%)

ARDS: Acute respiratory distress syndrome
ITP: Immune thrombocytopenic purpura

applied to 30 (13.5%) and 4 (1.8%) patients, respectively.
Four patients among 30 patients followed with prone
position died.
Independent risk factors for SARI/critical disease are
given in Table 8. It was found that patients older than 65
years have 8-fold increased risk for development of SARI/
critical disease.
4. Discussion
This study reveals the epidemiological and clinical
characteristics, and the factors and parameters that
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Table 5. Laboratory findings of COVID-19 patients on admission
All patients
median (min–max)

Mild disease and
pneumonia (n = 172)

SARI and critical disease (n
P-value
= 50)

White blood cell count (×109/L)

5290 (1150–21850)

5170 (1150–19900)

5900 (3610–21850)

0.005

Neutrophil count (×10 /L)

3300 (290–19800)

3180 (290–13400)

4300 (2300–19800)

<0.001

Lymphocyte count (×109/L)

1120 (150–4110)

1220 (380–4410)

770 (150–2090)

<0.001

Neutrophil/ Lymphocyte ratio

3 (0.4–38)

2.5 (0.4–28)

5.6 (1.5–38)

<0.001

Monocyte count (×10 /L)

330 (100–1460)

330 (100–1460)

290 (100–1260)

0.036

13.8 (7.1–17.3)

13.2 (8.6–16.7)

0.093

9

9

Hemoglobin (g/L)
Platelet count (×10 /L)

13.8 (7.1–17.3)

210.000(8.8000–499.000)

185.000 (100.000–406.000)

0.022

ALT, U/L

27 (7–408)

25 (7–123)

27 (9–408)

<0.001

AST, U/L

26 (7–321)

24 (7–122)

36 (14–321)

0.017

Total bilirubin (μmol/L)

0.5 (0.1–2.4)

0.5 (0.1–2.4)

0.6 (0.2–1.8)

0.024

Albumin (g/L)

41 (22–54)

44 (33–52)

40 (22–49)

<0.001

Creatinine (μmol/L)

0.85 (0.4–1.8)

0.82 (0.4–1.2)

0.95 (0.8–1.8)

<0.001

eGFR (mL/min/1.73m )

93 (9–139)

97 (15–139)

77.5 (9–122)

<0.001

C-reactive protein (mg/L)

0.155 (0.005–0.252)

0.009 (0.005–0.240)

0.089 (0.03–0.252)

0.996

Procalcitonin (PCT) (μg/L)

0.05 (0.001–37)

0.03 (0.001–3.0)

0.46 (0.001–37)

0.411

Troponin (μg/L)

5.5 (1–56)

3 (2–56)

10 (1–42)

0.313

Myoglobin (μg/L)

53 (8–502)

33 (8–134)

141 (23–502)

0.042

T. cholesterol (mg/dL)

145 (45–211)

185 (159–211)

102 (90–114)

0.567

Triglyceride (mg/dL)

107 (10–319)

117 (111–123)

137 (80–94)

0.063

PT

12.4 (10.7–15.9)

12.2 (10.7–17)

13.0 (11.6–15.9)

0.552

aPTT

24.9 (19.3–33.5)

24.9 (20–33.5)

24.7 ± 2.9

0.859

INR

1.03 (0.9–1.37)

1.03 (0.9–2.6)

1.08 (0.98–1.37)

0.911

Ferritin (μg/L)

141 (0.96–1566)

96 (0.96–956)

433 (11–1566)

<0.001

D-dimer (μg/L)

2.1 (0.01–35)

0.33 (0.01–35)

0.95 (0.42–1.37)

0.141

Fibrinogen (g/L)

3.1 (1–8.6)

2.9 (1–7.3)

4.9 (2.3–8.6)

<0.001

Creatine Kinase (μ/L)

88 (16–5395)

82 (16–1161)

128 (29–5395)

0.016

LDH (U/L)

216 (122–892)

209 (122–622)

308 (153–892)

<0.001

IL-6 (pg/mL)

16.5 (2.4–168)

10 (2.4–49)

43 (4–168)

<0.001

9

2

determine the clinical course and prognosis of the
COVID-19 patients admitted to the largest referral hospital
in Europe. Since it is a referral hospital, this study contains
valuable data in terms of the course of complicated patients
and provides a wide range spectrum of clinical picture of
COVID-19 patients.
Turkey has followed closely the developments related
to the disease, and immediately implemented many
preventive measures starting from the onset of the
epidemic. These rapid and important actions have given
time to be prepared for both the community and the
health care system in Turkey during this pandemic. As of
June 13, 2020, there are 176,677 cases and the mortality
rate is 2.7% in Turkey. This mortality rate is lower when

compared with the majority of countries across Europe, the
Americas, and Asia. Since our hospital is a referral center
for COVID-19 patients, the majority of the cases were
transferred from secondary and tertiary care hospitals
when their clinical conditions worsened. Consequently,
the mortality rate reported in this study (5.4%) is higher
than Turkey’s general mortality rate, but still lower than
the global rate of 6.9%. Feng et al. reported a mortality
rate in their study population that consists of COVID-19
patients from 3 different cities in China as 8% [2].
Richardson et al. reported 5700 hospitalized COVID-19
patients admitted to 12 hospitals in New York City [3] and
found a mortality rate of 21%, and an ICU admission rate
of 14.2%. In comparison, in this study, the mortality rate
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Table 6. Chest CT findings on admission of COVID-19 patients.
All patients

Disease severity

(n=215/222)
7 patients had no CT

Mild disease and
pneumonia (n=167/172)

SARI and critical disease
(n= 48/50)

P-value

Normal

26 (12.1%)

142 (75.1%)

1/48 (3.8%)

0.012

Consolidation

31 (14.4%)

22 (13.2)

9 (18.8%)

0.332

Unilateral ground-glass opacity

42 (19.5%)

42 (25.1%)

0/48 (0%)

<0.001

Bilateral ground-glass opacity

131 (60.9%)

87 (52.1%)

44 (91.7%)

<0.001

Patchy infiltration

20 (9.3%)

9 (5.4%)

11 (22.9%)

<0.001

Crazy paving

21 (9.8%)

13 (7.8)

8 (16.7%)

0.066

Pleural effusion

4 (1.9%)

3 (1.8%)

1 (2.1%)

1

Nodular lesion

26 (12.1%)

21 (12.6%)

4 (8.3%)

0.41

Halo or reverse halo

13 (6.1%)

12 (7.2%)

1 (2.1%)

0.306

Air bronchogram

5 (2.3%)

5 (3.0)

-

0.589

LAP

17 (7.9%)

13 (7.8%)

4 (8.3)

0.901

LAP: lymphadenopathy
Table 7. Supportive treatment regimens of the patients.
n (%)
Steroid

8 (3.6%)

Tocilizumab

12 (5.4%)

Anakinra

10 (4.5%)

Convalescent plasma

2 (0.9)

Mesenchimal stem cell

5 (2.3)

Intravenous Immunoglobulin

5 (0.3)

High dose vitamin C

11 (5.0)

Colchicine

11 (5.0)

Low molecular weight heparin (n=215)

89 (%41.3)

in Ankara City Hospital is considerably lower and ICU
admission rate is higher (18.9%). Wang et al. reported that
26% of patients required intensive care unit treatment,
and mortality was 4.3% [4]. These results might indicate
that the transfer of patients to ICU at an appropriate time
can be associated with low mortality. In many countries,
mortality rates are higher than ICU admission rates. This
may be a consequence of insufficient ICU beds. Turkey
has the highest number of ICU beds per 100,000 citizens
among highly populated countries. Ankara City Hospital
was able to reserve 200 of its 800 ICU beds to COVID-19
patients and therefore was able to accept a high number
of referral patients from healthcare facilities in Ankara
and surrounding provinces. All patients deemed to
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require intensive care by their physicians were able to be
transferred to an ICU in Ankara City Hospital without
undue delay.
Severe disease in COVID-19 can occur in healthy
individuals of any age. However, it is predominantly
observed in adults with comorbidity like cardiovascular
disease, diabetes mellitus, hypertension, chronic obstructive
pulmonary disease, and malignancies [5]. In our study, at
least one comorbidity was present in 92 (41.4%) patients.
The presence of comorbidity, especially coronary artery
disease and chronic obstructive pulmonary disease, was
significantly higher in the SARI/critical disease group (P <
0.05). The CDC COVID-19 Response Team reported that
among 7162 cases, 37.6% had one or more comorbidity
or risk factors [6]. The presence of at least 1 underlying
health condition or risk factor was found to be associated
with a higher hospitalization and ICU admission rate.
A metaanalysis reviewing 13 studies with 3027 patients
revealed that hypertension, diabetes, cardiovascular
disease, and respiratory disease were significantly higher in
critical/mortal patients compared to noncritical patients,
with odds ratios of 2.72, 3.68, 5.19, 5.15, respectively [7].
Since the angiotensin-converting enzyme 2 (ACE2) is the
cellular receptor for SARS-CoV-2, discussions about the
course of COVID-19 in patients using ACEI or ARB have
been present since the beginning of the outbreak. In this
study, we found no relationship between ACEI or ARB use
and severity of COVID-19. In a large retrospective cohort
study, prior ACEI/ARB use was not found to be associated
with increased mortality [8]. In another similar study from
Wuhan, authors concluded that taking ACEIs/ARBs is
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Table 8. Independent risk factors for SARI and critical disease
P value

Odds Ratio

95% C.I
Lower

Upper

Age (>65 years)

<0.001

8.071

3.362

19.374

Sex (male)

0.157

1.730

0.810

3.697

Hypertension

0.492

0.492

0.175

1.383

Coronary artery disease

0.621

1.439

0.340

6.092

COPD

0.134

2.822

0.728

10.944

Diabetes mellitus

0.524

1.398

0.499

3.913

Time for negative test after first symptom

0.787

0.989

0.914

1.070

Duration from illness onset to admission

0.519

0.964

0.862

1.078

Logistic regression analysis (“Enter” method. Nagelkerke R Sguare=0.226 )
COPD: Chronic obstructive pulmonary disease

not a risk factor for severe disease or mortality [9]. In the
current literature, there is insufficient evidence-based data
revealing that ACEI/ARB use will worsen the course of
COVID-19. Our results are in agreement with the current
guidelines which recommend all patients who have started
any ACE inhibitor/ARB to continue their medication.
In our patient population, age remains the only
independent risk factor for SARI/critical disease. It was
found that patients older than 65 years have an 8-fold
increased risk for the development of SARI/critical disease.
In a study comparing clinical characteristics of COVID-19
patients at different ages found that patients older than 60
years have heavier clinical course, poorer outcome, and
longer disease courses compared with those under 60
years [10]. The CDC reported that the case-fatality rate
increases with increasing age, from 0 among people aged
up to 19 years to 10%–27% among people aged 85 years
or more [6]. Xie et al. evaluated 168 fatal COVID-19 cases
and reported that median age was 70 years, and 95.8% of
these patients were older than 50 years [11].
There is no specific clinical feature that can reliably
differentiate COVID-19 from other viral respiratory
infections. The most common symptoms, fever and cough,
have been reported at varying rates in different articles.
In our study, cough and fever were the most observed
symptoms on admission, 58.1% and 48.6%, respectively.
The duration of symptoms is an important parameter
for clinicians. In our cohort, the most rapidly resolving
symptom was sore throat with median 2 days (1–11
days), and the frequency of sore throat was significantly
higher in the mild disease group when compared to SARI/
critical disease group (19.8% vs. 4%). Although the first
reported cases had isolated respiratory symptoms, with the
progression of the pandemic and the increasing number

of patients it was observed that olfactory and gustatory
dysfunction, which indicates nervous system involvement,
were also important symptoms of COVID-19. In a
systematic review and metaanalysis regarding olfactory
and gustatory dysfunction in COVID-19 patients, the
prevalence of anosmia and taste disorder were found to
be 52.73% (95% CI, 29.64%–75.23%) and 43.93% (95%
CI, 20.46%–68.95%), respectively [12]. In our study,
anosmia and loss of taste were observed 8.6% and 7.7%
of the patients, respectively. These symptoms may have
been overlooked since it is unlikely for someone who is
seriously ill to notice the loss of taste and smell unless
specifically asked. Although there is no specific symptom
in COVID-19, the coexistence of some symptoms like fever
and anosmia or loss of taste can increase the likelihood of
diagnosis.
Determining the laboratory tests that will contribute
to the follow-up of COVID-19 patients has an important
role for identifying severe and nonsevere cases or patients
with low or high mortality risk. Leukocytosis, an increase
in neutrophils and a decrease in lymphocytes, monocytes,
and eosinophils can be observed in COVID-19 [13,14].
These findings can be monitored by an increase in the
neutrophil/lymphocyte ratio (NLR). We found that median
NLR on admission are 2.5 (0.4–28) in the mild disease/
pneumonia group and 5.6 (1.5–38) in the SARI/critical
disease group. This ratio can help physicians to predict
the patient’s prognosis. In a retrospective, multicenter
cohort study, lymphocyte count was significantly higher in
nonfatal cases when compared to fatal cases; in survivors,
lymphocyte count improved after 7th day of illness whereas
severe lymphopenia continued until death in patients who
died [15]. We found that elevated liver enzymes, low GFR,
high levels of myoglobulin and creatine kinase, and high
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levels of ferritin and IL-6 on admission were found to be
associated with SARI/critical disease (P < 0.05). Zhang et
al. reported that IL-6 levels were 5 pg/mL and 35 pg/mL
in discharged and deteriorated patients, respectively [16].
In our patients, median and highest levels IL-6 levels on
admission were 10 pg/mL and 49 pg/mL in mild disease/
pneumonia group and 43 pg/mL and 168 pg/mL in SARI/
critical disease group. These results indicate that high
levels of IL-6 can be an early warning for cytokine storm
and poor prognosis on admission. All severe COVID-19
cases should be monitored for hyperinflammation. It is
important to recognize a life-threatening cytokine storm
early and identify subgroups that may benefit from
immunosuppressive agents. The most used supportive
treatment agent was tocilizumab (12 patients, 5.4%) in our
study.
The most unfavorable prognostic symptom in
COVID-19 is the development of coagulopathy and
its incidence has not been established. Like in sepsis,
complement activation, endothelial damage, and
inflammatory and microthrombotic pathway activation
can predispose to thrombosis. In our study, complications
regarding thrombosis were observed in 4 patients.
Wichmann et al. found deep venous thrombosis in 7 of
12 patients (58%) during autopsies of COVID-19 cases
where no venous thromboembolism was suspected before
death; the cause of death was determined as pulmonary
embolism in 4 patients [17].

Supportive treatment remains vital for COVID-19
patients. Clinicians should monitor patients closely for
the need for oxygen therapy and intensive care. Oxygen
therapy was required in 56 (25.2%) of our patients and
among 222 patients, 42 (18.9%) were followed up in the
ICU.
In conclusion, this first cohort study regarding
COVID-19 cases in Turkey reveals the epidemiological
and clinical characteristics, and the factors and parameters
that determine the clinical course and prognosis of the
COVID-19 patients admitted to the largest referral hospital
in Europe. Older age (>65), presence of comorbidity
(especially coronary artery disease and chronic obstructive
pulmonary disease), bilateral ground-glass opacity and
patchy infiltration on CT, low lymphocyte count, high
neutrophil/lymphocyte ratio, low monocyte count, low
platelet count, elevated liver enzymes, low GFR, high levels
of muscle enzymes, and high levels of ferritin and IL-6 on
admission are predictors of SARI and severe disease.
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